RAC1 as a Therapeutic Target in Malignant Melanoma

Alexa C. Cannon, Cristina Uribe-Alvarez, Jonathan Chernoff

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Small GTPases of the RAS and RHO families are related signaling proteins that, when activated by growth factors or by mutation, drive oncogenic processes. While activating mutations in KRAS, NRAS, and HRAS genes have long been recognized and occur in many types of cancer, similar mutations in RHO family genes, such as RAC1 and RHOA, have only recently been detected as the result of extensive cancer genome-sequencing efforts and are linked to a restricted set of malignancies. In this review, we focus on the role of RAC1 signaling in malignant melanoma, emphasizing recent advances that describe how this oncoprotein alters melanocyte proliferation and motility and how these findings might lead to new therapeutics in RAC1-mutant tumors.

Original languageEnglish
Pages (from-to)478-488
Number of pages11
JournalTrends in Cancer
Issue number6
StatePublished - Jun 2020


  • cancer therapeutics
  • driver mutations
  • effectors
  • fast-cycling
  • malignant melanoma
  • signal transduction
  • small GTPases


Dive into the research topics of 'RAC1 as a Therapeutic Target in Malignant Melanoma'. Together they form a unique fingerprint.

Cite this